Abstract
Ethanol-inducible CYP2E1 is an enzyme of major toxicological interest because it metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. CYP2E1 has also been implicated in alcohol liver disease because of its contribution to oxidative stress. Previously, polymorphic alleles with mutations in introns and in the 5′-flanking regulatory region have been described, and their presence has been related to the incidence of alcohol liver disease and lung cancer. In the present investigation, we investigated whether any functional mutations are linked to the above-mentioned rare alleles and also screened for mutations in the open reading frame using single-stranded conformation polymorphism and genomic DNA from almost 200 individuals belonging to either a Chinese, an Italian, or a Swedish population. Two new CYP2E1 gene variants were found with functional mutations: one (CYP2E1*2) in which a G1168A point mutation in exon 2 caused an R76H amino acid substitution, and the other (CYP2E1*3) in which a G10059A base substitution in exon 8 yielded a V389I amino acid exchange. The corresponding CYP2E1 cDNAs were constructed, subcloned into the pCMV4 expression vector, and expressed in COS-1 cells. The cellular levels of CYP2E1 mRNA, CYP2E1 protein, and rate of chlorzoxazone hydroxylation were monitored. The CYP2E1*3 cDNA variant was indistinguishable from the wild-type cDNA on all variables investigated, whereas CYP2E1*2 cDNA, although yielding similar amounts of mRNA, only caused 37% of the protein expression and 36% of the catalytic activity compared with the wild-type cDNA. Complete screening by single-stranded conformation polymorphism of the three populations studied revealed that these variant alleles were rare. We conclude that the humanCYP2E1 gene is functionally surprisingly well conserved compared with other cytochrome P450 enzymes active in drug metabolism, which suggests an important endogenous function in humans.
Footnotes
-
Send reprint requests to: Magnus Ingelman-Sundberg, Ph.D., Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, S-171 77 Stockholm, Sweden. E-mail:maging{at}ki.se
-
↵1 A new nomenclature system has recently been proposed for CYP2D6 alleles (40). This system is based on general recommendations for allele nomenclature, and the different alleles are denoted CYP2D6*n. Each allele is assigned a specific number. In accordance with this, we propose a similar system for designation of the CYP2E1 alleles with the following numbers: CYP2E1*1, wild-type sequence; CYP2E1*2, G1168A R76H; CYP2E1*3G10059A V389I.
-
↵2 Y. Hu, unpublished observations.
-
↵3 I. Dupont, D. Lucas, P. Clot, M. Seccia, C. Menez, and E. Albano, submitted for publication.
-
This work was supported by grants from The Swedish Alcohol Research Fund and from The Swedish Medical Research Council.
- Abbreviations:
- P450
- cytochrome P450
- PCR
- polymerase chain reaction
- RFLP
- restriction fragment length polymorphism
- SSCP
- single-stranded conformation polymorphism
- Received July 15, 1996.
- Accepted December 5, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|